A structured medical weight loss program using FDA-approved GLP-1 weight loss medications such as semaglutide and tirzepatide
Vision changes including blurred vision
Other notable greenlights this year include Bristol Myers Squibbs Cobenfy, the first novel therapeutic for schizophrenia in 35 years, and Madrigal Pharmaceuticals Rezdiffra, the first-ever treatment for MASH
Key Benefits: Reduces the appearance of dark spots and hyperpigmentation Deeply hydrates and nourishes the skin Promotes a brighter, more even complexion Antioxidant-rich formulation to combat free radicals Lightweight and easily absorbed for a smooth finish Main Ingredients: Glutathione known for its brightening and detoxifying properties, helps reduce dullness and dark spots
For semaglutide, that typically means beginning at 0.25mg weekly and increasing gradually
We understand how concerning GLP-1 shortages can be and are actively monitoring the situation